Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors

Cancer Immunol Immunother. 2010 Feb;59(2):183-93. doi: 10.1007/s00262-009-0757-9. Epub 2009 Sep 16.
No abstract available

Publication types

  • Review

MeSH terms

  • Adult
  • Animals
  • Antigens, Neoplasm / genetics
  • Antigens, Neoplasm / immunology*
  • Apoptosis / genetics
  • Apoptosis / immunology
  • Brain Neoplasms / therapy*
  • Cancer Vaccines / therapeutic use
  • Child
  • Clinical Trials as Topic
  • Humans
  • Immunotherapy / methods*
  • Inhibitor of Apoptosis Proteins
  • Mice
  • Microtubule-Associated Proteins / antagonists & inhibitors*
  • Microtubule-Associated Proteins / genetics
  • Microtubule-Associated Proteins / immunology
  • Neoplasm Proteins / antagonists & inhibitors*
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / immunology
  • Neovascularization, Pathologic / genetics
  • Neovascularization, Pathologic / immunology
  • Neovascularization, Pathologic / therapy
  • Survivin

Substances

  • Antigens, Neoplasm
  • BIRC5 protein, human
  • Cancer Vaccines
  • Inhibitor of Apoptosis Proteins
  • Microtubule-Associated Proteins
  • Neoplasm Proteins
  • Survivin